Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

The biology and management of non-small cell lung cancer

Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228

Metastasis: from dissemination to organ-specific colonization

Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2622 · Cited by 2,716

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545

EGFR Antagonists in Cancer Treatment

Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,849

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765

Lung cancer in never smokers — a different disease

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2190 · Cited by 1,601

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,437

A compendium of mutational cancer driver genes

Martínez-Jiménez, F., Muiños, F., Sentís, I., Deu-Pons, J., Reyes-Salazar, I., Arnedo-Pac, C., Mularoni, L., Pich, O., Bonet, J., Kranas, H., et al. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0290-x · Cited by 1,340

Kinase-targeted cancer therapies: progress, challenges and future directions

Bhullar, K. S., Orrego-Lagarón, N., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,316

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183

Anoikis molecular pathways and its role in cancer progression

Paoli, P., Giannoni, E., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.026 · Cited by 1,160

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083

Mechanisms of receptor tyrosine kinase activation in cancer

Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991

The cancer biomarker problem

Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 993

EGFR Mutations and Lung Cancer

Santos, G. D. C., Shepherd, F. A., & Tsao, M. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130206 · Cited by 964

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 930

An overview of the c-MET signaling pathway

Organ, S. L., & Tsao, M. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 879

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Zhang, Y., Yuan, J.-Q., Wang, K., Fu, X., Han, X., Threapleton, D. E., Yang, Z., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 866

Drug development of MET inhibitors: targeting oncogene addiction and expedience

Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 832

Cell death-based treatment of lung adenocarcinoma

Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768

Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival

Landi, M. T., Dracheva, T., Rotunno, M., Figueroa, J. D., Liu, H., Dasgupta, A., Mann, F. E., Fukuoka, J., Hames, M. L., Bergen, A. W., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001651 · Cited by 679

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665

WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis

Nguyen, D. X., Chiang, A. C., Zhang, X. H.-F., Kim, J. Y., Kris, M. G., Ladanyi, M., Gerald, W. L., & Massagué, J. (2009) · Journal of End-to-End-testing · doi:10.1016/j.cell.2009.04.030 · Cited by 627

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 615

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2820 · Cited by 600

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 587

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571

Molecular targeted therapy for anticancer treatment

Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555

KRAS Mutations in Non-Small Cell Lung Cancer

Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550

Epidermal growth factor receptor targeting in cancer: a review of trends and strategies

Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429

Biomedical Applications of Tetrazine Cycloadditions

Devaraj, N. K., & Weissleder, R. (2011) · Accounts of Chemical Research · doi:10.1021/ar200037t · Cited by 519

Planning cancer control in Latin America and the Caribbean

Goss, P. E., Lee, B. L., Badovinac-Črnjević, T., Strasser‐Weippl, K., Chávarri-Guerra, Y., Louis, J. S., Villarreal-Garza, C. M., Unger‐Saldaña, K., Ferreyra, M., Debiasi, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70048-2 · Cited by 523

Rational combinations of targeted cancer therapies: background, advances and challenges

Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500

RAB31 marks and controls an ESCRT-independent exosome pathway

Wei, D., Zhan, W., Gao, Y., Huang, L., Gong, R., Wang, W., Zhang, R., Wu, Y., Gao, S., & Kang, T. (2020) · Cell Research · doi:10.1038/s41422-020-00409-1 · Cited by 512

The EGFR Family: Not So Prototypical Receptor Tyrosine KinasesPreprint

Lemmon, M. A., Lemmon, M. A., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 472

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Shi, F., Telesco, S., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 485

Targeting the RAF–MEK–ERK pathway in cancer therapy

Montagut, C. O., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 466

Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis

Kim, Y.-N., Koo, K. H., Sung, J. Y., Yun, U.-J., & Kim, H. (2012) · International Journal of Cell Biology · doi:10.1155/2012/306879 · Cited by 480

Challenges and Opportunities in Cancer Drug Resistance

Ward, R. A., Fawell, S. E., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 461

Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint

Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 451

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Sequist, L. V. D., Besse, B., Lynch, T. J., Miller, V. A., Wong, K., Gitlitz, B. J., Eaton, K. D., Zacharchuk, C., Freyman, A., Powell, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9414 · Cited by 437

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Park, J. H., Liu, Y., Lemmon, M. A., & Radhakrishnan, R. (2012) · Biochemical Journal · doi:10.1042/bj20121513 · Cited by 432

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 437

Eph Receptor Signaling and EphrinsPreprint

Lisabeth, E. M., Falivelli, G., & Pasquale, E. B. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009159 · Cited by 448

Blood platelets contain tumor-derived RNA biomarkers

Nilsson, R. J. A., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., Widmark, A., Gerritsen, W. R., Verheul, H. M. W., Vandertop, W. P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-344408 · Cited by 401

Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses

Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400

Genomic alterations in lung adenocarcinoma

Devarakonda, S. H. K., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 423

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Dias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 393

A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy

Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103811 · Cited by 394

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients

Yung, T., Chan, K. C. A., Mok, T. S. K., TONG, J. H. M., To, K., & Lo, Y. M. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2622 · Cited by 386

Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/ trans ‐Cyclooctene Cycloaddition

Devaraj, N. K., Upadhyay, R., Haun, J. B., Hilderbrand, S. A., & Weissleder, R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200903233 · Cited by 380

Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

Chen, M. H., Kerkelä, R., & Force, T. L. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 377

EGFR signaling pathway as therapeutic target in human cancers

Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390

A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor

Kovács, E., Zorn, J. A., Huang, Y., Barros, T. F., & Kuriyan, J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034402 · Cited by 371

Heterogeneity in Lung Cancer

de Sousa, V. M. L., & Carvalho, L. (2018) · Pathobiology · doi:10.1159/000487440 · Cited by 383

Structure-Based View of Epidermal Growth Factor Receptor Regulation

Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368

Oncogenic EGFR Signaling Networks in Glioma

Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 371

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Yap, T. A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J., Temple, G., Bell, S., Shahidi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7278 · Cited by 349

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 358

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Le, X., Nilsson, M. B., Goldman, J. W., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt‐Moller, B., Wolff, K., Visseren‐Grul, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 357

Structure-based design of targeted covalent inhibitors

Lonsdale, R., & Ward, R. A. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00220c · Cited by 344

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 350

The epidermal growth factor receptor: from development to tumorigenesis

Sibilia, M. C., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00238.x · Cited by 349

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Shi, Y. K., Wang, L., Han, B. H., Li, W., Yu, P., Liu, Y. P., Ding, C. M., Song, X., Ma, Z. Y., Ren, X. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx359 · Cited by 287

Advances in covalent kinase inhibitors

Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 337

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Sequist, L. V. D., Gettinger, S. N., Senzer, N. N., Martins, R. G., Janne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 331

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

Brewer, M. R., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 323

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314

Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer

Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Wang, S., Cang, S., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0268-z · Cited by 312

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance

Wang, S., Song, Y., & Liu, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 309

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 306

Translating insights from the cancer genome into clinical practice

Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 304

Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases

Moritz, A., Yu, L., Guo, A., Villén, J., Wang, Y., MacNeill, J., Kornhauser, J. M., Sprott, K. M., Zhou, J., Possemato, A. P., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000998 · Cited by 300

Convergence between Wnt-β-catenin and EGFR signaling in cancer

Hu, T., & Li, C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-236 · Cited by 291

Oncogenic Mutations of PIK3CA in Human Cancers

Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291

Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M., & Merk, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0138 · Cited by 286

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156